Licolin

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Licolin

Property Description
Active Ingredient Irbesartan
Form Oral Tablet
Pharmacological Class Angiotensin II Receptor Blocker (ARB)
Common Use Blood pressure lowering (Antihypertensive)
Origin Synthetic Compound

Licolin is an orally administered prescription medication specifically formulated for the long-term management of high blood pressure, known as hypertension. Its core active compound is Irbesartan, the sole active pharmaceutical ingredient in this product. This compound belongs to the highly specific pharmacological classification known as Angiotensin II Receptor Blockers (ARBs), which is also commonly referred to as the Sartan drug class. The use of Irbesartan for cardiovascular regulation is clinically recognized for its sustained efficacy across numerous pharmacological studies, providing a reliable method of systemic blood pressure control. This medication is a synthetic, single-ingredient product supplied as an oral tablet for systemic use.


What is the General Purpose of Licolin (Irbesartan)?

The general therapeutic purpose of Licolin is to achieve sustained blood pressure lowering through a targeted biochemical intervention. The drug’s utility is derived from its ability to block the action of a potent, naturally occurring signaling hormone called Angiotensin II. By antagonizing the effect of this hormone, Irbesartan prevents blood vessels from constricting and tightening, thereby facilitating their vascular relaxation and easing the pressure on the circulatory system. ARBs effectively reduce the resistance against which the heart pumps blood. This means the medicine helps the circulatory system work more smoothly and efficiently, making it fundamentally useful for controlling hypertension and supporting overall cardiovascular function.


Composition and Origin: Is Licolin Natural or Synthetic?

Licolin utilizes the active ingredient Irbesartan, which is a synthetic compound; its consistent chemical structure is achieved through manufacturing processes rather than extraction from a natural source. Chemically, Irbesartan is a non-peptide tetrazole derivative. As an oral solid preparation, the final product is a tablet that consists of the precise quantity of the active component combined with essential solid pharmaceutical excipients that create a stable matrix necessary for reliable oral delivery of the medication. As a prescription-only product, Licolin is designed specifically for use in adult patients requiring systemic and targeted cardiovascular regulation.

What side effects are possible with Licolin?

Possible side effects and safety information

The safety profile of Licolin, which contains the active ingredient Irbesartan, is established through official documentation that classifies potential effects based on their documented frequency in clinical use. These adverse reactions are categorized by the physiological system affected and are subject to specific regulatory warnings.

Documented Frequency Classifications and Associated Effects

Adverse reactions are formally classified by frequency in regulatory documents. Common adverse reactions (occurring in 1 to 10 out of 100 patients) often involve the central nervous system and general conditions, including Dizziness, Headache, and Fatigue. Gastrointestinal effects like Nausea/Vomiting and Diarrhea are also listed as common. Less frequently observed reactions, categorized as Uncommon, include Tachycardia, Chest pain, and Sexual dysfunction.

Serious Safety Considerations

The regulatory profile documents serious adverse reactions, which, though often rare, are clinically significant. These include Angioedema (severe swelling of the face, lips, and throat) and the risk of Fetal Toxicity, which is a severe safety constraint leading to the medication being contraindicated during the second and third trimesters of pregnancy.

Safety Patterns and Restrictions

Certain safety patterns are noted based on exposure. Symptomatic Hypotension (excessively low blood pressure) is reported as more likely to occur at the beginning of treatment in specific patients, such as those who are volume-depleted. The official labeling also includes restrictions, such as the contraindication against combining Irbesartan with Aliskiren in patients with diabetes or existing renal impairment. These classifications define the drug's safety boundaries.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for an overdose of Licolin (Irbesartan) is based on anticipated extensions of its blood-pressure-lowering effect. Regulatory information notes that no data are available regarding overdosage in humans, although high daily doses have been reported as tolerated in studies.


Documented Clinical Manifestations

  • The most likely manifestations of overdosage are expected to be marked hypotension (low blood pressure) and tachycardia (fast heart rate); bradycardia (slow heart rate) might also occur.
  • Associated clinical signs stemming from severe hypotension include dizziness and fainting (syncope).

Required Emergency Actions

The need for urgent medical help is mandated for severe signs of overexposure, which include:

  • Collapse or inability to be awakened.
  • Having a seizure or experiencing trouble breathing.

In these situations, emergency services (911) must be contacted immediately. Treatment is officially defined as symptomatic and supportive. Regulatory documents also state that Irbesartan is not removed by hemodialysis, which is a key toxicological consideration. No specific antidote is formally documented in the official labeling.

Therapeutic Uses of Licolin

What Licolin Treats: Main Uses and Benefits

Licolin is considered relevant for providing supportive therapeutic benefit and focusing on symptomatic relief across various acute presentations. It is used in situations involving certain distressing symptoms that create noticeable interference with functional stability. It is often used during phases when symptoms become more noticeable. It helps address symptoms related to physical discomfort and those that create noticeable physiological strain.


Managing Symptom Load and Discomfort

This medication is commonly used when supportive symptom management is appropriate, particularly for symptoms associated with acute or episodic changes and recurrent manifestations. Licolin helps address symptom clusters that may become intense or disruptive, contributing to easing the overall symptom load during symptomatic periods. It is applied in clinical settings that involve acute or unstable symptom patterns, assisting with the management of symptoms that interfere with daily functioning. Licolin supports general well-being during symptomatic phases.

“Licolin is applied in contexts where additional symptomatic support is needed to address groups of symptoms that may appear suddenly.”

Quick Fact: Relief for Acute Discomfort Licolin is relevant for easing symptoms associated with acute or episodic changes, and may help patients cope more steadily with symptom fluctuations.

Eligibility and Restrictions for Use

Who Can and Cannot Use Licolin (Irbesartan)?

Licolin's eligibility profile, based on official regulatory documents, defines who may safely use this medication.

Populations Excluded or Restricted

Category Eligibility Rule
Absolute Contraindication Contraindicated for patients with known hypersensitivity to irbesartan or any component of the product.
Pregnancy Status Contraindicated during the second and third trimesters of pregnancy. Use must be discontinued immediately upon detection of pregnancy.
Concomitant Therapy Contraindicated in patients with diabetes mellitus or certain levels of renal impairment who are also taking aliskiren.
Pediatric Use Not established and not recommended for use in children and adolescents.
Lactation Not recommended for breastfeeding women.

Populations Requiring Caution

Use is established primarily in the adult population. Special caution is indicated for patients with volume depletion, who must have the condition corrected before starting Licolin. Use is not recommended for conditions like Primary Aldosteronism or in patients with severe hepatic impairment due to insufficient clinical data. No general dosage adjustment is necessary for mild to moderate hepatic impairment or most forms of renal impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Licolin (Irbesartan) is defined by its effects on the Renin-Angiotensin-Aldosterone System (RAAS) and its documented metabolic pathways.

Pharmacodynamic and Pharmacokinetic Interactions

Co-administration with Aliskiren is a formally documented contraindication in patients with diabetes mellitus or moderate to severe renal impairment. Concomitant use with Lithium may lead to toxicity due to reduced renal clearance of Lithium and subsequently elevated serum concentrations. Dual blockade of the RAAS, such as with ACE inhibitors, is generally not recommended due to increased risks of hypotension, hyperkalemia, and decreased renal function.

Licolin is primarily oxidized by the CYP2C9 enzyme; therefore, co-administration with inhibitors, such as Fluconazole, increases Irbesartan exposure. Furthermore, Licolin has the potential to inhibit the OATP1B1 transporter, resulting in officially documented increases in the plasma levels of co-administered medicines, such as Repaglinide.

Substance and Condition-Specific Constraints

Using Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including selective COX-2 inhibitors, may attenuate the blood pressure lowering effect and increase the risk of acute renal failure and hyperkalemia. This risk is specifically noted as being higher in the elderly and patients with existing poor renal function. Co-administration with Potassium-sparing Diuretics or potassium-containing salt substitutes increases the risk of hyperkalemia. Alcohol may lead to additive hypotensive effects, but no clinically relevant interaction is documented with food.

Mechanism of Action

Targeted Inhibition of Microbial Protein Synthesis

Licolin functions as an inhibitor that selectively targets and binds to the 50S ribosomal subunit within susceptible microorganisms . By physically occupying this site, the drug prevents the proper functioning of the enzyme peptidyl transferase, thereby directly interfering with the crucial molecular pathway of protein synthesis. This mechanistic interference blocks the capability of the microorganism to form the peptide bonds necessary to link amino acids and assemble polypeptide chains. The interruption of this process prevents the microorganisms from synthesizing the essential structural and functional proteins required for growth and cellular function.

Halting Microbial Elongation and Proliferation

The interruption of the protein synthesis pathway modifies the resulting molecular cascade by causing a functional block of the elongation phase of translation. This mechanistic activity results in an arrested growth and division among the target microorganisms. The resulting physiological effect is a reduction in the microbial population within the affected system, limiting the prevalence of the organisms.

Dosage and Administration Information

How to Use Licolin

The usage of Licolin (Irbesartan) is structured around a continuous, once-daily pattern for long-term chronic management. The medication is delivered exclusively via the oral route as a tablet and can be administered with or without food.


Official Dosing Guidelines

The official dosage range is defined to establish a stable regimen, with specific starting points for different patient needs.

Usage Parameter Instruction
Standard Initial Dose 150 mg once daily
Typical Maintenance Dose 150 mg or 300 mg once daily
Maximum Dose 300 mg once daily

Procedural and Population-Specific Rules

Licolin is intended for long-term therapy, and it may take approximately two to four weeks for the medication's full effect to be observed following a dose change. The tablet must be swallowed whole with water to ensure proper administration.

Special Conditions and Dose Adjustments:

  • Volume-Depleted Patients: A lower initial dose of 75 mg once daily is recommended for patients who are intravascularly volume or salt depleted (e.g., those on high-dose diuretic therapy).
  • Elderly Patients (>75 years): A lower starting dose of 75 mg may be considered.

If a dose is missed, patients should simply take the next scheduled dose at the usual time; two doses should never be taken at the same time to compensate for a missed dose.

Recent Clinical Evidence

Research Evidence: Overview of Clinical Studies for Licolin (Irbesartan)


Evidence for Use in Managing Essential Hypertension

Licolin's active ingredient has been studied extensively in numerous short-term Randomized Controlled Trials (RCTs) examining high blood pressure. These studies were conducted primarily on adult patients diagnosed with mild to moderate high blood pressure. Researchers typically compared the evaluation of the active ingredient against an inactive placebo or against other existing medicines used for high blood pressure management. The primary focus of this research was the measurement of changes in systolic and diastolic blood pressure readings over the study period.

These short-term trials described patterns observed in the measurement of blood pressure readings that were related across the studied populations. However, because these were short-term efficacy studies, they primarily relied on measuring blood pressure numbers, which are known as surrogate endpoints. Long-term effects are not fully established by these initial studies, as they do not provide extensive data on whether these blood pressure changes relate to major cardiovascular events, such as heart attack or stroke, over many years.


Evidence for Use in Managing Nephropathy in Type 2 Diabetes

Research has specifically evaluated the active ingredient in patients with Type 2 Diabetes and documented kidney damage (nephropathy). This research involved large-scale, long-term outcome trials that were designed to observe patients over several years. These long-term studies monitored defined renal composite endpoints, such as the time it took for patients to experience outcomes like a doubling of serum creatinine or the eventual need for dialysis or a kidney transplant. The reported data described patterns related to renal outcomes among the observed populations over these extended time intervals.

It is important to note that the most consistent evidence is primarily related to the Type 2 diabetic population with existing kidney problems. Data for certain groups remain insufficient, as the evidence exploring similar outcomes for patients with Type 1 diabetes or kidney disease from other causes is limited.


What Remains Uncertain About the Research

Research on Licolin's active ingredient contributes to the understanding of outcomes related to blood pressure and kidney function, yet key research limitations still exist. The evidence quality varies across studies, and some areas rely heavily on data showing an association rather than a direct, confirmed cause-and-effect relationship regarding long-term health. Certainty remains low in areas where studies have not yet provided sufficient data, such as for the evaluation of heart complications in patients with heart failure where findings were mixed in large studies.

Frequently Asked Questions (FAQ)

Common questions about Licolin (FAQ)

Q: Why is Licolin only available by prescription?

A: Licolin is classified as a prescription-only (Rx) medication. This is because it is intended for the long-term management of chronic conditions, such as high blood pressure. These conditions require professional diagnosis and where ongoing medical supervision and monitoring of the condition are considered necessary.

Q: Does Licolin cause weight gain?

A: Official regulatory data classifies weight gain as an uncommon side effect of Licolin. This means it has been reported infrequently in clinical studies. It is not considered one of the most frequently observed effects.

Q: Can Licolin affect my sleep?

A: Official labeling includes sleep disturbance as a reported side effect, although it is considered uncommon or less frequent. Changes to normal sleep pattern have been reported in regulatory safety profiles as an uncommon side effect.

Q: Does Licolin have a generic version available?

A: Yes, the active ingredient in Licolin, which is Irbesartan, is available as a generic medication in various markets. The availability of generic Irbesartan may vary depending on your specific location.

Q: Does Licolin interact with blood thinners?

A: Regulatory reviews have generally stated that no significant interactions have been identified between Irbesartan and warfarin, a commonly used blood thinner (anticoagulant).

Q: Does Licolin require any special monitoring while using it?

A: Yes, due to its mechanism, periodic monitoring of serum potassium levels and kidney function (creatinine) is formally advised in official documentation, especially for patients with existing risk factors. These tests help healthcare providers monitor your condition while on the medicine.

Q: Are there known interactions between Licolin and herbal remedies?

A: While general herbal remedies are not listed, official guidance advises against the use of supplements and substances that can increase potassium levels. Because Licolin can raise your blood potassium, combining it with other potassium sources increases the risk of hyperkalemia, or excessively high potassium.

Q: Is Licolin a controlled substance?

A: No, Licolin (Irbesartan) is not scheduled under the Controlled Substances Act (CSA). It is therefore not classified as a controlled drug or a substance with a high potential for abuse.

Q: Where can I find the official regulatory information (FDA/EMA) on Licolin?

A: Official documentation for Licolin can be found on government health authority websites. You can search for the FDA DailyMed label for the U.S. information or the EMA Summary of Product Characteristics (SmPC) for European regulatory details, both of which are publicly available.

Q: Can Licolin affect my ability to drive or operate machinery?

A: Regulatory documents advise caution when driving or operating machinery. This is because Licolin can commonly cause side effects like dizziness or fatigue, which may affect your concentration or coordination. It is important to know how the medicine affects you before engaging in these activities.

Q: How does Licolin affect the [relevant body system, e.g., nervous system]?

A: Licolin primarily acts on the circulatory system to lower blood pressure. Its effects on the central nervous system (CNS) are primarily indicated through reported adverse events in the regulatory safety profile. These common effects include feeling dizzy or having a headache.

Q: What if Licolin doesn't seem to be working for me after a few weeks?

A: Licolin is intended for long-term management. The full therapeutic effect may take approximately two to four weeks to be observed following a dose change, as noted in official instructions. A lack of full effect before this period is generally considered not unusual.

Q: Does the age of a patient affect how Licolin works?

A: Official guidance indicates that while the drug's processing (pharmacokinetics) is altered in the elderly, no general dose adjustment is necessary for age alone. However, a lower starting dose may be considered for patients over 75 years of age.

Q: Can I use Licolin if I have a history of heart issues?

A: The drug is used to treat high blood pressure, a heart-related condition. However, caution is required, as studies involving patients with severe heart failure had mixed findings. The use of this medication requires careful consideration based on the patient's full medical history.

Q: Are there any specific foods or drinks to avoid while using Licolin?

A: Official guidance advises against the use of potassium-containing salt substitutes and potassium supplements. This is because Licolin can raise blood potassium levels, and combining it with other potassium sources increases the risk of hyperkalemia.

Q: Does Licolin need to be used at the same exact time every day?

A: Licolin is a once-daily medication. Taking it around the same time every day may help support consistent blood pressure control, which is the aim of long-term therapy.

Q: Are there different strengths or forms of Licolin available?

A: Yes, Licolin (Irbesartan) is an oral medication that is available as a tablet in different strengths. The official product information typically lists strengths of 75 mg, 150 mg, and 300 mg.

Q: Why do official documents mention 'unknown risk' for certain groups?

A: The mention of 'unknown risk' or 'insufficient data' is a standard regulatory requirement. It is a formal way to state that the medicine's effects and safety have not yet been adequately studied in specific populations, such as in cases of severe hepatic impairment or certain rare conditions.

How should Licolin be stored and disposed of?

How to Store and Dispose of Licolin (Irbesartan)

Official labeling for Licolin (Irbesartan) oral tablets establishes mandatory conditions for storage and disposal to maintain potency and ensure safety.


Storage Conditions

  • The tablets must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), while protecting the medicine from freezing, excess heat, and moisture.
  • The product should be kept in its original container with the lid tightly closed.
  • It is mandatory to keep this medication out of the sight and reach of children.

Disposal Instructions

  • Unused or expired product must be disposed of in accordance with local requirements.
  • The preferred methods are utilizing a drug take-back program or mail-back envelope.
  • Irbesartan is not on the FDA flush list and should not be thrown into wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Licolin found in:

A-Z Index: